{"success":true,"data":{"pressRelease":{"id":"168143","rtpr_id":"nBw18MCHRa-20261013","ticker":"QGEN","exchange":"NYSE","all_tickers":["QGEN","QIA"],"title":"QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis","author":"Business Wire","published_at":"2026-10-13T20:05:00.357Z","article_body":"QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge\nProgress Against Tuberculosis\n\n\n * Global TB Summit brings together international experts as persistent disease\nburden and funding pressures challenge progress against tuberculosis\n\n * QuantiFERON-TB Gold Plus detects tuberculosis (TB) infection as an aid to\nidentify people eligible for preventive treatment while supporting clinical\nevaluation of suspected TB disease\n\n * More than a decade of QIAGEN-supported education connects clinicians,\nlaboratories, researchers, advocates and public health leaders\n\nQIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together\ntuberculosis experts from around the world for the Global TB Clinical and\nEducational Summit from October 13-16 as a persistent disease burden and\ngrowing pressures on global health funding put renewed focus on tuberculosis\nprevention, screening and care.\n\nAn estimated 10.7 million people worldwide developed tuberculosis in 2024 and\nnearly 1.2 million died from the disease, according to the World Health\nOrganization’s (WHO) Global Tuberculosis Report 2025. While global TB deaths\nhave declined, the number of people developing the disease remains\npersistently high, underscoring the need to sustain prevention, detection and\ntreatment efforts.\n\nThe Summit comes as cuts to international health funding put TB programs under\ngrowing pressure. The WHO has warned that reductions in donor funding threaten\nessential TB prevention as well as diagnostic and treatment services. A key\ndiscussion on October 15, “TB at risk – the global consequences of funding\ncuts and the future of tuberculosis control,” will bring together experts\nfrom academia, clinical practice, advocacy and international TB organizations.\n\n“The world has made progress against tuberculosis, but that progress cannot\nbe taken for granted,” said Dr. Christine Ginocchio, Chief Medical Officer\nat QIAGEN. “Millions of people still develop TB every year, and pressure on\nfunding and public health systems could slow further advances. Bringing\nexperts together, strengthening education and identifying people with TB\ninfection are practical ways we can help sustain momentum toward better\nprevention and care.”\n\nQIAGEN supports TB control through both education and diagnostic testing. Its\nactivities include the annual Global TB Clinical and Educational Summit and\nQuantiFERON-TB Gold Plus (QFT-Plus), a blood-based interferon-gamma release\nassay used to detect TB infection and TB disease.\n\nQFT-Plus can be used to detect TB infection as an aid to identify people who\nmay benefit from preventive treatment, particularly those at increased risk\nfor TB disease. More than 160 million QuantiFERON-TB tests have been sold\nworldwide since launch, with customers in more than 130 countries and more\nthan 2,700 peer-reviewed publications involving QuantiFERON.\n\nFor more than a decade, the Global TB Clinical and Educational Summit has\nbrought together clinicians, laboratory professionals, researchers, nurses,\nadvocates, survivors and public health leaders to exchange knowledge and\nexperience in TB detection, treatment, prevention and patient care.\n\nThe 2026 Global TB Summit, under the theme “One world, one fight: Let’s\nend TB together,” will take place online from October 13-15 and online and\non-site at the Royal College of Physicians in London on October 16.\n\nDiscussions will focus on major challenges facing TB control, including\nprevention and screening, drug‑resistant and childhood TB, vulnerable\npopulations and access to care. Sessions will also examine the role of\ninterferon-gamma release assays in screening people at increased risk of\ndeveloping TB disease, including patients receiving kidney dialysis or\nbiologic therapy, immunocompromised patients and older adults.\n\nThe Summit is free to attend and offers CME- and CPD-accredited learning.\n\nFurther information on the program and registration is available at\nhttps://www.qiagen.com/knowledge-and-support/knowledge-hub/events-and-webinars/tb-summit\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.qiagen.com%2Fknowledge-and-support%2Fknowledge-hub%2Fevents-and-webinars%2Ftb-summit&esheet=54621219&newsitemid=20261013545546&lan=en-US&anchor=https%3A%2F%2Fwww.qiagen.com%2Fknowledge-and-support%2Fknowledge-hub%2Fevents-and-webinars%2Ftb-summit&index=1&md5=7c9c0348bde389870cb5b9ffd635988b)\n\nAbout QIAGEN\n\nQIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample\nto Insight solutions that enable customers to extract and analyze molecular\ninformation from biological samples containing the building blocks of life.\nOur Sample technologies isolate and process DNA, RNA and proteins from blood,\ntissue and other materials. Assay technologies prepare these biomolecules for\nanalysis, while bioinformatics support the interpretation of complex data to\ndeliver actionable insights. Automation solutions integrate these steps into\nstreamlined, cost-effective workflows. QIAGEN serves more than 500,000\ncustomers worldwide in the Life Sciences (academia, pharmaceutical R&D and\nindustrial applications such as forensics) and Molecular Diagnostics (clinical\nhealthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across\nmore than 35 locations. For more information, visit www.qiagen.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qiagen.com&esheet=54621219&newsitemid=20261013545546&lan=en-US&anchor=www.qiagen.com&index=2&md5=15f07bb9090fb1989b28226c0334e076)\n.\n\nForward-Looking Statement\n\nCertain statements in this press release may constitute forward-looking\nstatements within the meaning of the U.S. federal securities laws. These\nstatements include, among others, statements regarding QIAGEN’s products,\nproduct development and launches, regulatory approvals, market opportunities\nand future business performance. Forward-looking statements are based on\ncurrent expectations and assumptions and involve risks and uncertainties that\ncould cause actual results to differ materially. These risks include, among\nothers, the development and commercial success of new products, regulatory\napprovals, competition, changes in customer demand and funding, economic and\nmarket conditions, supply chain disruptions, cybersecurity incidents,\nlitigation and other risks described under “Risk Factors” in QIAGEN’s\nmost recent Annual Report on Form 20-F and other filings with the U.S.\nSecurities and Exchange Commission. QIAGEN undertakes no obligation to update\nany forward-looking statement except as required by law.\n\nSource: QIAGEN N.V.\n\nCategory: Infectious Diseases\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013545546/en/\n(https://www.businesswire.com/news/home/20261013545546/en/)\n\nQIAGEN:\n\nPublic Relations \n\ne-mail: pr@QIAGEN.com (mailto:pr@QIAGEN.com)\n\nInvestor Relations \n\ne-mail: ir@QIAGEN.com (mailto:ir@QIAGEN.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw18MCHRa-20261013","title":"QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis","author":"Business Wire","ticker":"QGEN","created":"2026-10-13T20:05:00.357Z","tickers":["QGEN","QIA"],"exchange":"NYSE","article_body":"QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge\nProgress Against Tuberculosis\n\n\n * Global TB Summit brings together international experts as persistent disease\nburden and funding pressures challenge progress against tuberculosis\n\n * QuantiFERON-TB Gold Plus detects tuberculosis (TB) infection as an aid to\nidentify people eligible for preventive treatment while supporting clinical\nevaluation of suspected TB disease\n\n * More than a decade of QIAGEN-supported education connects clinicians,\nlaboratories, researchers, advocates and public health leaders\n\nQIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together\ntuberculosis experts from around the world for the Global TB Clinical and\nEducational Summit from October 13-16 as a persistent disease burden and\ngrowing pressures on global health funding put renewed focus on tuberculosis\nprevention, screening and care.\n\nAn estimated 10.7 million people worldwide developed tuberculosis in 2024 and\nnearly 1.2 million died from the disease, according to the World Health\nOrganization’s (WHO) Global Tuberculosis Report 2025. While global TB deaths\nhave declined, the number of people developing the disease remains\npersistently high, underscoring the need to sustain prevention, detection and\ntreatment efforts.\n\nThe Summit comes as cuts to international health funding put TB programs under\ngrowing pressure. The WHO has warned that reductions in donor funding threaten\nessential TB prevention as well as diagnostic and treatment services. A key\ndiscussion on October 15, “TB at risk – the global consequences of funding\ncuts and the future of tuberculosis control,” will bring together experts\nfrom academia, clinical practice, advocacy and international TB organizations.\n\n“The world has made progress against tuberculosis, but that progress cannot\nbe taken for granted,” said Dr. Christine Ginocchio, Chief Medical Officer\nat QIAGEN. “Millions of people still develop TB every year, and pressure on\nfunding and public health systems could slow further advances. Bringing\nexperts together, strengthening education and identifying people with TB\ninfection are practical ways we can help sustain momentum toward better\nprevention and care.”\n\nQIAGEN supports TB control through both education and diagnostic testing. Its\nactivities include the annual Global TB Clinical and Educational Summit and\nQuantiFERON-TB Gold Plus (QFT-Plus), a blood-based interferon-gamma release\nassay used to detect TB infection and TB disease.\n\nQFT-Plus can be used to detect TB infection as an aid to identify people who\nmay benefit from preventive treatment, particularly those at increased risk\nfor TB disease. More than 160 million QuantiFERON-TB tests have been sold\nworldwide since launch, with customers in more than 130 countries and more\nthan 2,700 peer-reviewed publications involving QuantiFERON.\n\nFor more than a decade, the Global TB Clinical and Educational Summit has\nbrought together clinicians, laboratory professionals, researchers, nurses,\nadvocates, survivors and public health leaders to exchange knowledge and\nexperience in TB detection, treatment, prevention and patient care.\n\nThe 2026 Global TB Summit, under the theme “One world, one fight: Let’s\nend TB together,” will take place online from October 13-15 and online and\non-site at the Royal College of Physicians in London on October 16.\n\nDiscussions will focus on major challenges facing TB control, including\nprevention and screening, drug‑resistant and childhood TB, vulnerable\npopulations and access to care. Sessions will also examine the role of\ninterferon-gamma release assays in screening people at increased risk of\ndeveloping TB disease, including patients receiving kidney dialysis or\nbiologic therapy, immunocompromised patients and older adults.\n\nThe Summit is free to attend and offers CME- and CPD-accredited learning.\n\nFurther information on the program and registration is available at\nhttps://www.qiagen.com/knowledge-and-support/knowledge-hub/events-and-webinars/tb-summit\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.qiagen.com%2Fknowledge-and-support%2Fknowledge-hub%2Fevents-and-webinars%2Ftb-summit&esheet=54621219&newsitemid=20261013545546&lan=en-US&anchor=https%3A%2F%2Fwww.qiagen.com%2Fknowledge-and-support%2Fknowledge-hub%2Fevents-and-webinars%2Ftb-summit&index=1&md5=7c9c0348bde389870cb5b9ffd635988b)\n\nAbout QIAGEN\n\nQIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample\nto Insight solutions that enable customers to extract and analyze molecular\ninformation from biological samples containing the building blocks of life.\nOur Sample technologies isolate and process DNA, RNA and proteins from blood,\ntissue and other materials. Assay technologies prepare these biomolecules for\nanalysis, while bioinformatics support the interpretation of complex data to\ndeliver actionable insights. Automation solutions integrate these steps into\nstreamlined, cost-effective workflows. QIAGEN serves more than 500,000\ncustomers worldwide in the Life Sciences (academia, pharmaceutical R&D and\nindustrial applications such as forensics) and Molecular Diagnostics (clinical\nhealthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across\nmore than 35 locations. For more information, visit www.qiagen.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qiagen.com&esheet=54621219&newsitemid=20261013545546&lan=en-US&anchor=www.qiagen.com&index=2&md5=15f07bb9090fb1989b28226c0334e076)\n.\n\nForward-Looking Statement\n\nCertain statements in this press release may constitute forward-looking\nstatements within the meaning of the U.S. federal securities laws. These\nstatements include, among others, statements regarding QIAGEN’s products,\nproduct development and launches, regulatory approvals, market opportunities\nand future business performance. Forward-looking statements are based on\ncurrent expectations and assumptions and involve risks and uncertainties that\ncould cause actual results to differ materially. These risks include, among\nothers, the development and commercial success of new products, regulatory\napprovals, competition, changes in customer demand and funding, economic and\nmarket conditions, supply chain disruptions, cybersecurity incidents,\nlitigation and other risks described under “Risk Factors” in QIAGEN’s\nmost recent Annual Report on Form 20-F and other filings with the U.S.\nSecurities and Exchange Commission. QIAGEN undertakes no obligation to update\nany forward-looking statement except as required by law.\n\nSource: QIAGEN N.V.\n\nCategory: Infectious Diseases\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013545546/en/\n(https://www.businesswire.com/news/home/20261013545546/en/)\n\nQIAGEN:\n\nPublic Relations \n\ne-mail: pr@QIAGEN.com (mailto:pr@QIAGEN.com)\n\nInvestor Relations \n\ne-mail: ir@QIAGEN.com (mailto:ir@QIAGEN.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-13T20:05:00.430740662Z","server_sent_at_ms":1791921900430},"received_at":"2026-10-13T20:05:00.490Z","source_url":"https://www.businesswire.com/news/home/20261013545546/en/"},"analysis":{"id":"156431","press_release_id":"168143","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["WHO warns reductions in donor funding threaten TB prevention, diagnostic and treatment services -- potential headwind for TB diagnostics demand"],"eventType":"other","narrative":"QIAGEN is convening its annual Global TB Clinical and Educational Summit from October 13-16, 2026, online and at the Royal College of Physicians in London.\n\nThe company cited WHO data estimating 10.7 million TB cases and nearly 1.2 million deaths in 2024, and flagged cuts to international health funding as a growing pressure on TB programs.\n\nThe summit showcases QuantiFERON-TB Gold Plus, QIAGEN's blood-based TB infection test, which has sold more than 160 million tests across 130+ countries since launch.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Brand/educational event release for QGEN; note funding-cut warnings as a soft watch item for its TB diagnostics franchise."},"keyFigures":{"customDimensions":{"tb_cases_2024":"10.7 million","tb_deaths_2024":"nearly 1.2 million","countries_served":"more than 130","quantiferon_tests_sold":"more than 160 million","peer_reviewed_publications":"more than 2,700"}},"quotedText":"The world has made progress against tuberculosis, but that progress cannot be taken for granted","namedEntities":{"people":[{"name":"Dr. Christine Ginocchio","role":"Chief Medical Officer at QIAGEN"}],"products":["QuantiFERON-TB Gold Plus (QFT-Plus)"],"companies":[{"name":"QIAGEN N.V.","ticker":"QGEN","relationship":"filer"},{"name":"World Health Organization","relationship":"data source / public health body"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Corporate-communications release promoting QIAGEN's Global TB Summit and its QuantiFERON-TB Gold Plus franchise. No financial results, guidance, or business developments; largely brand/educational content."},"tickerRelevance":{"others":[],"primary":"QGEN"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap-mid-profile","eventGravity":"corporate-communications-event","issuerAuthored":true,"financialContent":"none"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"QIAGEN is convening its annual Global TB Clinical and Educational Summit from October 13-16, 2026, online and at the Royal College of Physicians in London.\n\nThe company cited WHO data estimating 10.7 million TB cases and nearly 1.2 million deaths in 2024, and flagged cuts to international health funding as a growing pressure on TB programs.\n\nThe summit showcases QuantiFERON-TB Gold Plus, QIAGEN's blood-based TB infection test, which has sold more than 160 million tests across 130+ countries since launch.","key_figures":{"customDimensions":{"tb_cases_2024":"10.7 million","tb_deaths_2024":"nearly 1.2 million","countries_served":"more than 130","quantiferon_tests_sold":"more than 160 million","peer_reviewed_publications":"more than 2,700"}},"named_entities":{"people":[{"name":"Dr. Christine Ginocchio","role":"Chief Medical Officer at QIAGEN"}],"products":["QuantiFERON-TB Gold Plus (QFT-Plus)"],"companies":[{"name":"QIAGEN N.V.","ticker":"QGEN","relationship":"filer"},{"name":"World Health Organization","relationship":"data source / public health body"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T20:05:10.424Z","global_importance":12,"audience_relevance":15,"importance_components":{"tickerTier":"large-cap-mid-profile","eventGravity":"corporate-communications-event","issuerAuthored":true,"financialContent":"none"}},"durationMs":4562,"modelName":"glm-5.3-flashx"}}